Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY TrialPrithviraj Bose, Nauman Butt, Sebastian Grosicki et al.|Journal of Clinical Oncology|2026Cited by 1
Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review studyJacqueline S. Garcia, Aaron D. Goldberg, P Desai et al.|Leukemia & lymphoma/Leukemia and lymphoma|2026Cited by 0